Therefore, we suggest that the pan-HER inhibitor may be a more appropriated therapeutic option for EML4-ALK-rearranged NSCLC after prolonged exposure to PEM, even though it has not been initially identified as having HER overexpression. The gene discussed is ALK; the disease is non-small cell lung carcinoma.